NARA Discovery
NARA Subscribed Scholarly Literature Discovery
Boolean search: climate AND coral · microplastic OR nanoplastic · plastic NOT freshwater · "marine heatwave"
Advanced Search
Topic searches article titles and abstracts. Starts a new search; publisher and year refine it.
Searches article titles and abstracts.
Accepts bare DOI, doi: prefix, or a doi.org URL.
Complete publisher name. Publisher imprints are grouped under their main publisher where applicable.
Exact match by full journal title or ISSN.
–
Refine Results Clear Filters
Collection
NARA Subscribed1
Publisher
Springer Nature1
Journal
Clinical & Experimental Metastasis1
Publication Year
20251
Akin Atmaca results 1 · Newest (Page 1/1, per page 25)
Export CSV Export RIS Export current results · up to 5,000 records
Author: Akin Atmaca ×Clear All Filters
Search Results
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)NARA Subscribed
Clinical & Experimental Metastasis · 2025 · Vol. 42 · Issue 5 · Springer
Farastuk Bozorgmehr; Inn Chung; Jürgen R. Fischer; Marc Bischof; Akin Atmaca; Sophie Wetzel; Martin Faehling; Dirk Bottke; Martin Wermke; Esther G. C. Troost; Cornelia Kropf-Sanchen; Thomas Wiegel; Bernd Schmidt; Andrej Stupavsky; Walburga Engel-Riedel; Michaela Hammer-Hellmig; Niels Reinmuth; Farkhad Manapov; Christian Grohe; Robert Krempien; Christian Schumann; Florian Sterzing; Martin Reck; Florian Würschmidt; Jochen Fleckenstein; Alev Petroff; Sven Henschke; Rouven Behnisch; Jelena Cvetkovic; Lena Brückner; Constantin Schwab; Albrecht Stenzinger; Thorsten Götze; Christina Kopp; Helge Schröder; Jürgen Debus; Petros Christopoulos; Michael Thomas; Stefan Rieken
Introduction of immune checkpoint inhibitors (ICI) has improved overall survival (OS) for advanced non-small cell lung cancer (NSCLC). However, responses differ greatly amongst patients. Additional radiotherapy (RT) may promote tumor-specific immunity and synergize with ICI to improve tumor control. The multicenter phase II FORCE trial evaluated safety and efficacy of nivolumab with additional palliative radiotherapy (5 × 4 Gy...
View Details View Full Text